Lundbeck’s acquisition of Longboard to significantly enhance its neuroscience pipeline

Lundbeck (NASDAQ: LUN) strengthened its neurology portfolio with the acquisition of Longboard Pharmaceuticals (NASDAQ: LBPH) in December 2024, gaining control of a promising experimental treatment for severe childhood epilepsies.

The deal gives the Danish drugmaker access to bexicaserin, Longboard’s lead asset, which is being developed to treat rare and hard-to-manage seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome. The therapy works by targeting the 5-HT2C receptor, a novel approach that has caught analysts’ attention for its potential to reshape treatment standards in this niche market.

According to Visible Alpha consensus estimates, bexicaserin could reach peak global sales of DKK6.7 billion globally by 2039. Its anticipated launch in 2028 is expected to play a key role in diversifying Lundbeck’s revenue base. While the drug is projected to contribute just 0.3% to Lundbeck’s total revenue upon its expected launch in 2028, it could account for as much as 27% by 2039. The timing aligns with the patent expiry of Rexulti in 2029, positioning bexicaserin as a critical driver of long-term growth.